Optimum Strategic Communications client, Ziylo, acquired by Novo Nordisk in deal that could exceed US$800m
Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients
New tools and technologies to streamline IR
PART TWO: The changing role of consensus
MiFID II and Consensus numbers, what does it mean for IR teams?
PART ONE: The changing role of Consensus. The new MiFID II rules are expected…
Living In The MIFID World – THURSDAY, 14 JUNE 2018
It is almost six months since MIFID II went live, Optimum Strategic Communications…
Highlights from the 9th Annual Healthcare Investor Conference at Bloomberg
Building billion-dollar healthcare businesses in Europe is dependent on a number of success factors…
